CDK4 and neoplasm: SRX3177 displayed greater tumor cytotoxicity as compared to the dual BRD4/PI3K inhibitor, SF2523 or dual BRD4/CDK4/6 inhibitor, SRX3177P (Supplementary Fig. S3).